Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo therapy offers hope for kids with hard-to-treat brain cancers

NCT ID NCT01356290

Disease control Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests a combination of drugs given in low, frequent doses to slow or stop the growth of recurrent brain tumors in children. The goal is to extend survival while maintaining quality of life. About 232 children with medulloblastoma, ependymoma, ATRT, or other rare CNS tumors will receive this anti-angiogenesis therapy. The study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 232 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2014

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 19 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for patients * Stratum I: Relapsed or progressive medulloblastoma - completed * Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease) * Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease) * Stratum IV: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease) * Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative) * Histological confirmation at diagnosis or relapse Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (Intensity Data; raw data of methylation array) * Female or male, aged from 0 to \<20 years (at time of original diagnosis) * Participants must have normal organ and bone marrow function (ALT \<5x institutional upper limit of normal, creatinine \<1.5x institutional upper limit of normal for age, WBC \>1000/mm3, platelets \> 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol * Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used * Written informed consent of patients and / or legal guardian Exclusion criteria for patients * VP- or subdural peritoneal shunt dependency (can be included in Stratum V) * Prior treatment with temozolomide/irinotecan (can be included in Stratum V) * Active infection, pregnancy or breast feeding * Treatment for current relapse (surgery may be performed before MEMMAT treatment; patients with sites of disease not irradiated are still eligible for the protocol) * Known hypersensitivity to any of the drugs in the protocol * Active peptic ulcer * Any significant cardiovascular disease not controlled by standard therapy e.g. systemic hypertension * Anticipation of the need for major elective surgery during the course of the study treatment * Any disease or condition that contraindicates the use of the study medication/treatment or places the patient at an unacceptable risk of experiencing treatment-related complications * Non-healing surgical wound * A bone fracture that has not satisfactorily healed

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrt recurrent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atypical teratoid rhabdoid tumor central nervous system neoplasm ependymoma medulloblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrt recurrent Ependymoma recurrent Medulloblastoma recurrent Rare CNS tumor recurrent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akademiska sjukhuset

    RECRUITING

    Uppsala, 751 85, Sweden

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    TERMINATED

    Chicago, Illinois, 60611-2605, United States

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69373, France

  • Centre Oscar Lambret

    TERMINATED

    Lille, 59037, France

  • Dana-Farber Cancer Institute and Boston Children's Hospital

    TERMINATED

    Boston, Massachusetts, 02215, United States

  • Dell Children's Medical Group SFC-HEM/ONC

    RECRUITING

    Austin, Texas, 78723, United States

  • Helen DeVos Children's Hospital

    RECRUITING

    Grand Rapids, Michigan, 48503, United States

  • Hospital Infantil Universitario Nino Jesus

    RECRUITING

    Madrid, 28009, Spain

  • Karolinska University Hospital

    RECRUITING

    Stockholm, SE-171 76, Sweden

  • Kepler Universitätsklinikum Med Campus IV

    RECRUITING

    Linz, 4020, Austria

  • Medical University of Graz

    RECRUITING

    Graz, 8036, Austria

  • Medical University of Innsbruck

    RECRUITING

    Innsbruck, 6020, Austria

  • Medical University of Vienna

    RECRUITING

    Vienna, 1090, Austria

  • Motol University Hospital Prague

    WITHDRAWN

    Prague, 15006, Czechia

  • Norrlands Universitetssjukhus

    RECRUITING

    Umeå, 901 85, Sweden

  • Onkologisk-hematologisk seksjon Barneklinikken Haukeland universitetssjukehus

    RECRUITING

    Bergen, Bergen, 5021, Norway

  • Sahlgrenska Universitetssjukhuset

    RECRUITING

    Gothenburg, 416 85, Sweden

  • Salzburger Universitätsklinikum

    RECRUITING

    Salzburg, 5020, Austria

  • Skånes universitetssjukhus

    RECRUITING

    Lund, 221 85, Sweden

  • Universitetssjukhuset Linköping

    RECRUITING

    Linköping, 581 85, Sweden

  • University Hospital Brno

    RECRUITING

    Brno, 61300, Czechia

  • University hospital Rigshospitalet

    RECRUITING

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.